Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Future Oncology (London, England)|November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancerBenjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
The Journal of Experimental Medicine|November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancerCamila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Pageof 17